The last two decades have seen great improvement in our ability to keep traumatically injured soldiers alive from wounds that previously would have proven fatal.  However, the result has been an increase in severe functional deficits due to loss of tissue and limbs. 
 
Harnessing stem cell therapies to regenerate lost or damaged tissue holds out hope for restoring our Wounded Warriors to full functionality and improving their quality of life.

• Learn what the Department of Defense (DoD) is doing to support cell therapies for traumatic injury
• Examine the manufacturing and regulatory roadblocks to cell therapies and tissue engineered medical products, and what can be done to overcome them
• See the work being done to manufacture red blood cells at scale and at point of need

Register now to discover some of the extraordinary work the DoD is doing in cell therapy and regenerative medicine to address traumatic injuries, especially those suffered by Military personnel.

SHARE THE SCIENCE
with
Lloyd Rose, PhD

Regenerative Medicine Portfolio Manager, Clinical and Rehabilitative Medicine Research Program
US Army Medical Material Development Activity

"Stem Cell Therapies for the Wounded Warrior"

Free webinar.  Open to the public.
​
Thursday, October 22nd - 2pm Eastern Time/ 11am Pacific Time

CLICK HERE TO WATCH THE RECORDING

We are thrilled to welcome Dr. Sairah Ahmed as our next featured speaker on Share the Science. We have had many requests from the Save the Cord community to highlight the latest research in CAR-T cell therapy and as it relates to cord blood. Indeed, this is a new and emerging area of scientific research with great promise. Given that we welcome not only healthcare professionals to our webinars but also the general public, we feel it is important to give you a brief overview of the basics regarding CAR-T cell therapy.

In this special webinar focused on CAR-T Cell Therapy, Dr. Ahmed will discuss how cord blood sources play a critical role in treating select lymphomas including the potential of using CAR-T cell therapy.  This method of treatment shows particular promise in treating lymphomas that are not responding to other methods. During Dr. Ahmed's presentation she will highlight which patients are the best candidates for treatment with CAR-T therapy and how is CAR-T therapy different from autologous transplant for lymphoma.  She will also discuss which types of lymphoma can be treated with CAR-T therapy.  The toxicity specific to CAR-T therapy, as well as novel lymphoma cellular therapy treatment from cord blood sources will also be discussed. 

SHARE THE SCIENCE
with
Sairah Ahmed, M.D.

Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine
​The University of Texas MD Anderson Cancer Center, Houston, TX

"Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Lymphoma"

Free webinar.  Open to the public.
​
Thursday, September 24th - 2pm Eastern Time/ 11am Pacific Time

RECORDING NOW AVAILABLE

Understanding the nuances of cord blood transplantation, pre- and post-transplant, are key to treating any patient undergoing this procedure.  Often the patient's survival and quality of life post-transplant is driven by their body's ability to rebuild the immune system. Join us on August 20th to learn how transplant doctors can exploit cord blood's unique qualities during this process of recovery and period of reconstitution. Dr. Jaap Boelens will present his latest research in this area and explain how reconstituting immune cells from cord blood differs from other stem cell sources. 

Many factors influence HCT outcomes, such as the selected graft source, type of infused cell subsets, cell doses, and the protocols used for conditioning, immune suppression, and treatment of adverse events. Recent pharmacokinetic studies show that compounds used in the conditioning regimen (e.g. busulphan, fludarabine, anti-thymocyte globulin) should use patient-specific dosing to achieve optimal exposure in every individual patient.

Attendees of this Share the Science webinar will learn:

• What unique anti-viral and tumor features are present in cord blood T cells
• How CD4+ reconstitution of only 50/uL is an excellent predictor for outcomes after transplantation
• Why the dosing of agents given in the conditioning regimen can have significant impact on reconstitution of immune cells
• Due to a multitude of variables, harmonization between HCT centers is still difficult to achieve. Dr. Boelens will share his investigations to improve immune recovery after HCT to limit both relapse and non-relapse mortality (death due to viral reactivations and graft-versus-host disease).

SHARE THE SCIENCE
with
Jaap Jan Boelens, MD, PhD

Chief, Stem Cell Transplantation and Cellular Therapies
Memorial Sloan Kettering Cancer Center

"Immune Reconstitution after Cord Blood Transplantation"

Free webinar.  Open to the public.
​
Thursday, August 20th - 12 noon Eastern Time/ 9am Pacific Time

RECORDING NOW AVAILABLE